PubMed:24403068 JSONTXT 41 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 108-282 DRI_Background denotes Recently, it was discovered that serglycin, a hematopoietic cell proteoglycan, is the major proteoglycan expressed and constitutively secreted by multiple myeloma (MM) cells.
T2 283-396 DRI_Background denotes High levels of serglycin are present in the bone marrow aspirates of at least 30% of newly diagnosed MM patients.
T3 397-463 DRI_Background denotes However, its contribution to the pathophysiology of MM is unknown.
T4 464-547 DRI_Outcome denotes Here, we show that serglycin knockdown (by ∼85% compared with normal levels), using
T5 564-652 DRI_Outcome denotes , dramatically attenuated MM tumor growth in mice with severe combined immunodeficiency.
T6 653-867 DRI_Approach denotes Tumors formed from cells deficient in serglycin exhibited diminished levels of hepatocyte growth factor expression and impaired development of blood vessels, indicating that serglycin may affect tumor angiogenesis.
T7 868-989 DRI_Background denotes Furthermore, knockdown of serglycin significantly decreased MM cell adhesion to bone marrow stromal cells and collagen I.
T8 990-1241 DRI_Outcome denotes Even though serglycin proteoglycan does not have a transmembrane domain, flow cytometry showed that serglycin is present on the MM cell surface, and attachment to the cell surface is, at least in part, dependent on its chondroitin sulfate side chains.
T9 1242-1500 DRI_Approach denotes Co-precipitation of serglycin from conditioned medium of MM cells using a CD44-Fc chimera suggests that CD44 is the cell surface-binding partner for serglycin, which therefore may serve as a major ligand for CD44 at various stages during myeloma progression.
T10 1501-1680 DRI_Outcome denotes Finally, we demonstrate that serglycin mRNA expression in MM cells is up-regulated by activin, a predominant cytokine among those increased in MM patients with osteolytic lesions.
T11 1681-1854 DRI_Background denotes These studies provide direct evidence for a critical role for serglycin in MM pathogenesis and show that targeting serglycin may provide a novel therapeutic approach for MM.